切换至 "中华医学电子期刊资源库"

中华肝脏外科手术学电子杂志 ›› 2024, Vol. 13 ›› Issue (06) : 876 -882. doi: 10.3877/cma.j.issn.2095-3232.2024026

基础研究

肝细胞癌VOPP1表达及其与预后的关系
陈晓鹏1, 王佳妮2, 练庆海3, 杨九妹4,()   
  1. 1.750002 银川,宁夏医科大学第三临床医学院
    2.510630 广州,中山大学附属第三医院乳腺与甲状腺外科
    3.510630 广州,中山大学附属第三医院疫苗研究所
    4.510317 广州,广东省第二人民医院医学实验中心
  • 收稿日期:2024-07-18 出版日期:2024-12-10
  • 通信作者: 杨九妹
  • 基金资助:
    广东省自然科学基金(2017A030313858)

Expression of VOPP1 in hepatocellular carcinoma and its relationship with prognosis

Xiaopeng Chen1, Jiani Wang2, Qinghai Lian3, Jiumei Yang4,()   

  1. 1.Third Clinical Medical College of Ningxia Medical University,Yinchuan 750002,China
    2.Department of Breast and Thyroid Surgery,the Trird Affiliated Hospital of Sun Yat-sen University,Guangzhou 510630,China
    3.Institute of Vaccine,the Trird Affiliated Hospital of Sun Yat-sen University,Guangzhou 510630,China
    4.Medical Experiment Center,Guangdong Second Provincial General Hospital,Guangzhou 510317,China
  • Received:2024-07-18 Published:2024-12-10
  • Corresponding author: Jiumei Yang
引用本文:

陈晓鹏, 王佳妮, 练庆海, 杨九妹. 肝细胞癌VOPP1表达及其与预后的关系[J]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 876-882.

Xiaopeng Chen, Jiani Wang, Qinghai Lian, Jiumei Yang. Expression of VOPP1 in hepatocellular carcinoma and its relationship with prognosis[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 876-882.

目的

探讨囊泡过表达肿瘤促生存蛋白1(VOPP1)在肝细胞癌(肝癌)中的表达及其与患者预后关系。

方法

回顾性分析2008年2月至 2015年8月在中山大学附属第三医院行根治性切除术的90例肝癌患者临床病理资料。患者均签署知情同意书,符合医学伦理学规定。其中男81例,女9例;年龄27~74岁,中位年龄53岁;TNM分期Ⅰ期11例,Ⅱ期29例,Ⅲ期26例,Ⅳ期2例;采用免疫组化法检测肝癌组织及癌旁组织VOPP1表达,分析VOPP1表达与临床病理指标之间的关系。另外收集10例患者肝癌组织及癌旁组织,采用qRT-PCR检测VOPP1 mRNA表达水平。生存分析采用Kaplan-Meier法和Log-rank检验,Cox回归模型分析患者预后的独立危险因素。

结果

qRT-PCR检测显示,肝癌组织VOPP1 mRNA平均相对表达量为(4.91±1.98)×10-3,明显高于配对癌旁组织的(0.39±0.12)×10-3t=2.284,P<0.05)。免疫组化法检测显示,肝癌组织VOPP1阳性表达率为52%(47/90),明显高于癌旁组织的28%(25/90) (χ2=11.204,P<0.05)。肝癌组织VOPP1高表达与组织学分级相关(χ2=9.373,P<0.05)。生存分析显示,VOPP1高表达组和低表达组肝癌根治性切除术患者的中位无复发生存期(RFS)分别为17、50个月,VOPP1高表达组患者的RFS明显低于VOPP1低表达组(χ2=7.769,P<0.05)。Cox回归分析显示,T3分期(HR=3.649,95%CI:1.278~10.420)、T4分期(HR=6.157,95%CI:1.297~29.235)和VOPP1蛋白高表达(HR=1.866,95%CI:1.069~3.258)均是影响患者术后RFS的独立危险因素(P<0.05)。

结论

VOPP1在肝癌组织中高表达,其表达水平与患者预后呈负相关,且是肝癌预后的独立危险因素,可作为一个有价值的预后预测新指标。

Objective

To investigate the expression of vesicular over-expressed in cancer prosurvival protein 1 (VOPP1) in hepatocellular carcinoma (HCC) and its relationship with clinical prognosis of HCC patients.

Methods

Clinicopathological data of 90 HCC patients who underwent radical resection in the Third Affiliated Hospital of Sun Yat-sen University from February 2008 to August 2015 were retrospectively analyzed. The informed consents of all patients were obtained and the local ethical committee approval was received. Among them,81 patients were male and 9 female,aged 27-74 years,with a median age of 53 years. 11 cases were classified as TNM stage Ⅰ,29 cases of TNM stage Ⅱ,26 cases of TNM stage Ⅲ and 2 cases of TNM stage Ⅳ. The expression level of VOPP1 in HCC and adjacent tissues was determined by immunohistochemical staining,and the relationship between VOPP1 expression and clinicopathological parameters was analyzed. In addition,the expression level of VOPP1 mRNA in the cancer and adjacent tissues of 10 HCC patients was detected by qRT-PCR. Survival analysis was conducted by Kaplan-Meier method and Log-rank test. The independent risk factors of clinical prognosis were assessed by Cox regression model.

Results

qRT-PCR showed that the average relative expression of VOPP1 mRNA in HCC tissues was (4.91±1.98)×10-3,significantly higher than (0.39±0.12)×10-3 in paired adjacent tissues (t=2.284, P<0.05). Immunohistochemical staining showed that the positive expression rate of VOPP1 in HCC was 52%(47/90),significantly higher than 28%(25/90) in adjacent tissues (χ2=11.204, P<0.05).The high expression of VOPP1 in HCC tissues was correlated with histological grade (χ2=9.373, P<0.05).Survival analysis showed that the median recurrence-free survival (RFS) of HCC patients with high and low expression of VOPP1 after radical resection was 17 and 50 months,respectively. The RFS of patients with high expression of VOPP1 was significantly lower than that of their counterparts with low expression of VOPP1 (χ2=7.769, P<0.05). Cox regression analysis showed that T3 stage (HR=3.649,95%CI: 1.278-10.420),T4 stage (HR=6.157,95%CI: 1.297-29.235) and high expression of VOPP1 protein (HR=1.866,95%CI: 1.069-3.258) were the independent risk factors of postoperative RFS (P<0.05).

Conclusions

VOPP1 is highly expressed in HCC tissues. The expression level of VOPP1 is negatively correlated with clinical prognosis. VOPP1 is an independent risk factor of clinical prognosis of HCC,which can be utilized as a new and valuable prognostic factor.

图1 VOPP1 mRNA在肝癌和癌旁组织中的表达 注:VOPP1为囊泡过表达肿瘤促生存蛋白1
图2 VOPP1在肝癌组织中免疫组化法染色情况(×200) 注:a为阴性表达,b为低表达,c为高表达;VOPP1为囊泡过表达肿瘤促生存蛋白1
表1 VOPP1表达与肝癌患者临床病理指标的关系(例)
图3 VOPP1不同表达情况的肝癌根治性切除术患者Kaplan-Meier生存曲线 注:VOPP1为囊泡过表达肿瘤促生存蛋白1
表2 肝癌患者预后影响因素Cox回归分析
[1]
Sung H,Ferlay J,Siegel RL,et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2021,71(3): 209-249.
[2]
Siegel R,Miller K,Wagle NS,et al. Cancer statistics,2023[J]. CA A Cancer J Clin,2023,73:17-48.
[3]
Wen N,Cai Y,Li F,et al. The clinical management of hepatocellular carcinoma worldwide: a concise review and comparison of current guidelines: 2022 update[J]. Biosci Trends,2022,16(1):20-30.
[4]
Xia C,Dong X,Li H,et al. Cancer statistics in China and United States,2022: profiles,trends,and determinants[J]. Chin Med J,2022,135(5):584-590.
[5]
Liu J,Zhao SY,Jiang Q,et al. Long noncoding RNA MYLK-AS1 promotes growth and invasion of hepatocellular carcinoma through the EGFR/HER2-ERK1/2 signaling pathway[J]. Int J Biol Sci,2020,16(11):1989-2000.
[6]
Ganesan P,Kulik LM. Hepatocellular carcinoma: new developments[J]. Clin Liver Dis,2023,27(1):85-102.
[7]
吴虹霖,牛翔科,熊燕,等. 肝细胞肝癌的免疫治疗现状及研究进展[J]. 中国免疫学杂志,2021,37(22):2771-2778.
[8]
郑荣寿,张思维,孙可欣,等. 2016年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志,2023,45(3):212-220.
[9]
Sugawara Y,Hibi T. Surgical treatment of hepatocellular carcinoma[J]. Biosci Trends,2021,15(3):138-141.
[10]
中华人民共和国国家卫生健康委员会. 原发性肝癌诊疗指南(2022年版)[J/OL]. 肿瘤综合治疗电子杂志,2022,8(2):16-53.
[11]
Pang BY,Leng Y,Wang X,et al. A meta-analysis and of clinical values of 11 blood biomarkers,such as AFP,DCP,and GP73 for diagnosis of hepatocellular carcinoma[J]. Ann Med,2023,55(1):42-61.
[12]
Park S,James CD. ECop (EGFR-coamplified and overexpressed protein),a novel protein,regulates NF-kappaB transcriptional activity and associated apoptotic response in an IkappaBalphadependent manner[J]. Oncogene,2005,24(15):2495-2502.
[13]
Baras AS,Solomon A,Davidson R,et al. Loss of VOPP1 overexpression in squamous carcinoma cells induces apoptosis through oxidative cellular injury[J]. Lab Invest,2011,91(8):1170-1180.
[14]
Gao C,Pang M,Zhou Z,et al. Epidermal growth factor receptorcoamplified and overexpressed protein (VOPP1) is a putative oncogene in gastric cancer[J]. Clin Exp Med,2015,15(4):469-475.
[15]
Mattern J,Koomägi R,Volm M. Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma[J]. Br J Cancer,1996,73(7):931-934.
[16]
Masuda H,Zhang D,Bartholomeusz C,et al. Role of epidermal growth factor receptor in breast cancer[J]. Breast Cancer Res Treat,2012,136(2):331-345.
[17]
Staudt C,Puissant E,Boonen M. Subcellular trafficking of mammalian lysosomal proteins: an extended view[J]. Int J Mol Sci,2016,18(1):47.
[18]
Li YJ,Zhang W,Xia H,et al. MiR-218 suppresses epithelial-tomesenchymal transition by targeting Robo1 and Ecop in lung adenocarcinoma cells[J]. Future Oncol,2017,13(28):2571-2582.
[19]
Karin M,Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity[J]. Annu Rev Immunol,2000,18:621-663.
[20]
Li JM,Zhang H,Zuo YJ. MicroRNA-218 alleviates sepsis inflammation by negatively regulating VOPP1 via JAK/STAT pathway[J]. Eur Rev Med Pharmacol Sci,2018,22(17):5620-5626.
[21]
Xia H,Yan Y,Hu M,et al. MiR-218 sensitizes glioma cells to apoptosis and inhibits tumorigenicity by regulating ECOP-mediated suppression of NF-κB activity[J]. Neuro Oncol,2013,15(4):413-422.
[22]
Sliwkowski MX,Mellman I. Antibody therapeutics in cancer[J].Science,2013,341(6151):1192-1198.
[23]
Bonin F,Taouis K,Azorin P,et al. VOPP1 promotes breast tumorigenesis by interacting with the tumor suppressor WWOX[J].BMC Biol,2018,16(1):109.
[1] 梁孟杰, 朱欢欢, 王行舟, 江航, 艾世超, 孙锋, 宋鹏, 王萌, 刘颂, 夏雪峰, 杜峻峰, 傅双, 陆晓峰, 沈晓菲, 管文贤. 联合免疫治疗的胃癌转化治疗患者预后及术后并发症分析[J]. 中华普外科手术学杂志(电子版), 2024, 18(06): 619-623.
[2] 张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[3] 屈翔宇, 张懿刚, 李浩令, 邱天, 谈燚. USP24及其共表达肿瘤代谢基因在肝细胞癌中的诊断和预后预测作用[J]. 中华普外科手术学杂志(电子版), 2024, 18(06): 659-662.
[4] 顾雯, 凌守鑫, 唐海利, 甘雪梅. 两种不同手术入路在甲状腺乳头状癌患者开放性根治性术中的应用比较[J]. 中华普外科手术学杂志(电子版), 2024, 18(06): 687-690.
[5] 付成旺, 杨大刚, 王榕, 李福堂. 营养与炎症指标在可切除胰腺癌中的研究进展[J]. 中华普外科手术学杂志(电子版), 2024, 18(06): 704-708.
[6] 公宇, 廖媛, 尚梅. 肝细胞癌TACE术后复发影响因素及预测模型建立[J]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 818-824.
[7] 李一帆, 朱帝文, 任伟新, 鲍应军, 顾俊鹏, 张海潇, 曹耿飞, 阿斯哈尔·哈斯木, 纪卫政. 血GP73水平在原发性肝癌TACE疗效评价中的作用[J]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 825-830.
[8] 刘敏思, 李荣, 李媚. 基于GGT与Plt比值的模型在HBV相关肝细胞癌诊断中的作用[J]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 831-835.
[9] 关小玲, 周文营, 陈洪平. PTAAR在乙肝相关慢加急性肝衰竭患者短期预后中的预测价值[J]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 841-845.
[10] 焦振东, 惠鹏, 金上博. 三维可视化结合ICG显像技术在腹腔镜肝切除术治疗复发性肝癌中的应用[J]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 859-864.
[11] 张润锦, 阳盼, 林燕斯, 刘尊龙, 刘建平, 金小岩. EB病毒相关胆管癌伴多发转移一例及国内文献复习[J]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 865-869.
[12] 李素娟, 王文玲, 董洪敏, 李小凯, 黄思成, 王刚. 多原发与单原发大肠腺癌的预后分析[J]. 中华消化病与影像杂志(电子版), 2024, 14(05): 407-412.
[13] 孙文恺, 沈青, 杭丽, 张迎春. 纤维蛋白原与清蛋白比值、中性粒细胞与白蛋白比值、C反应蛋白与溃疡性结肠炎病情评估和预后的关系[J]. 中华消化病与影像杂志(电子版), 2024, 14(05): 426-431.
[14] 郭曌蓉, 王歆光, 刘毅强, 何英剑, 王立泽, 杨飏, 汪星, 曹威, 谷重山, 范铁, 李金锋, 范照青. 不同亚型乳腺叶状肿瘤的临床病理特征及预后危险因素分析[J]. 中华临床医师杂志(电子版), 2024, 18(06): 524-532.
[15] 闫战涛, 王辉, 周梓迪, 史勇强, 陈铜兵. 胃淋巴上皮瘤样癌三级淋巴结构特征及其与预后的相关性[J]. 中华临床医师杂志(电子版), 2024, 18(05): 455-461.
阅读次数
全文


摘要